で公開中です！詳しく見る

OmniAb

OABI

時価総額 $6.67億

4.59 USD

-0.14

2.96%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

4.51

-0.08

1.74%

1日

-2.96%

5日間

-3.77%

1か月

5.52%

3か月

125%

6か月

194.23%

年初来

144.15%

1年

170%

5年間

-53.82%

10年間

-52.97%

概要： OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

従業員数： 89

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 28.6%

ニュートラル 71.4%

ネガティブ 0%

ニュートラル

OmniAb to Report Third Quarter 2026 Financial Results on October 30

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026, and will hold a conference call that same day beginning at 8:00 a.m. Eastern time. Conference Call and Webcast What: OmniAb conf.

OmniAb to Report Third Quarter 2026 Financial Results on October 30

ポジティブ

OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth

OmniAb NASDAQ: OABI used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides platform.

OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth

ニュートラル

OmniAb, Inc. (OABI) Analyst/Investor Day Transcript

OmniAb, Inc. (OABI) Analyst/Investor Day Transcript

OmniAb, Inc. (OABI) Analyst/Investor Day Transcript

ポジティブ

Zacks Investment Research

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy

OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy

ニュートラル

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration® platform, and introduces the OmniTides™ peptide discovery platform and brand. “We look forward to bringing together our investment com.

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

ニュートラル

OmniAb to Host Investor & Analyst Day on October 6, 2026

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA. The event will feature presentations from OmniAb's executive leadership team, including corporate updates, select partner programs, the xPloration® platform, technology innovations and a Q&A sessi.

OmniAb to Host Investor & Analyst Day on October 6, 2026

ニュートラル

OmniAb to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management's participation in the following upcoming investor conferences: Nasdaq/LD Micro Summit Series Date: Wednesday, September 9, 2026 H.C. Wainwright 28th Annual Global Investment Conference Date: Tuesday, September 15, 2026 The Nasdaq/LD Micro Summit will take place at the Nasdaq Headquarters in.

OmniAb to Participate in Upcoming Investor Conferences

ポジティブ

OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.

OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech

ニュートラル

OmniAb Raises 2026 Financial Guidance

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook,” stated Matt Foehr, Chief Executive Officer of Om.

OmniAb Raises 2026 Financial Guidance

ニュートラル

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and expertise in ion channel discovery and screening. “We are pleased to enter into this important new relationship with Lilly,” said M.

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています